Ripretinib (QINLOCK)
Criteria for Use
April 2022

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at *www.pbm.va.gov* or *PBM INTRAnet* for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive Ripretinib.

- ☐ CrCl <30 mL/min
- ☐ Moderate Hepatic Insufficiency defined as total bilirubin > 1.5 × ULN and any AST
- ☐ Clinically significant cardiovascular disease such as CHF (NYHA Class II to IV), active ischemia and/or angina Pectoris, baseline Left Ventricular Ejection Fraction < 50%
- ☐ Uncontrolled hypertension, ensure blood pressure control prior to starting therapy
- ☐ Major surgical procedure within prior 14 days or presence of active wound
- ☐ Pre-existing bleeding or coagulopathy
- ☐ Untreated brain metastases
- ☐ Hypersensitivity to ripretinib
- ☐ Unmanageable drug interaction with CYP3A inducers and/or inhibitors
- ☐ Pregnancy (known pregnancy or positive pregnancy test)
- ☐ Breastfeeding

Inclusion Criteria

The answers to ALL of the following must be fulfilled in order to meet criteria.

- ☐ Care is provided by a VA/VA Community Care oncology provider
- ☐ Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- ☐ Goals of care and role of Palliative Care consult have been discussed and documented
- ☐ Patients of child-bearing potential and patients with partners of child-bearing potential: counseling provided on contraception and risks vs. benefits of treatment. Use effective contraception during therapy and for one week after the last dose.

Additional Inclusion Criteria

The answer to the following must be fulfilled to meet criteria:

- ☐ Patients with gastrointestinal stromal tumors who have progressed or have unacceptable toxicity on three prior lines of therapy that includes imatinib, sunitinib, and regorafenib